#United States #New Orleans #gene therapy #PackGene #AAV Manufacturing

PackGene to Showcase Innovations at ASGCT 2025

PackGene Biotech, Inc. is set to make a significant impact at the American Society of Gene & Cell Therapy (ASGCT) 28th annual meeting, taking place from May 13-17, 2025, in New Orleans. The company plans to showcase six presentations focusing on its advanced technologies aimed at making gene therapy more accessible and affordable.

The presentations will highlight PackGene's commitment to delivering a comprehensive suite of innovative technology platforms and Contract Development & Manufacturing Organization (CDMO) solutions. These technologies are designed to accelerate the development of gene therapy while simultaneously lowering costs throughout the product lifecycle.

Key Highlights of PackGene’s Presentations

During the ASGCT meeting, PackGene's scheduled presentations will cover a variety of topics including:

• - High-Productivity AAV Manufacturing: Techniques in enhancing AAV production efficiency using plasmid modification and dual-plasmid systems.
• - AI-Driven Capabilities: Discussions on AI-assisted AAV capsid engineering designed for improved vector production.
• - Advanced Analytics: Robust analytics tools that are crucial for high-quality gene therapy manufacturing.
• - Immunogenicity Assessments: Carrying out assessments to ensure the safety and effectiveness of gene therapies.

Dr. Xin Swanson, Chief Strategy Officer at PackGene, emphasizes the company's mission: "At PackGene, our goal is to make gene therapy affordable. We are excited to showcase our progress towards this aim and tackle critical industry challenges." The demonstrations aim to lower costs of gene therapy by innovatively addressing issues such as vector tissue targeting, immunogenicity, safety, and manufacturability. The dedication of PackGene to support programs from research through to clinical trials underscores its collaborative efforts with academic institutions and industry partners.

Presentation Schedule

The following are key presentations PackGene will conduct:

• - Driving Down Costs: Advancing AAV Manufacturing for Affordable Gene Therapy

- Date: May 16th, 2 PM
- Location: Exhibit Hall Presentation Theater

• - Advancing AAV Capsid Engineering for Targeted Gene Therapy Using PackGene's π-Icosa Platform (AMA1046)

- Date: May 13th, 6 PM - 7:30 PM
- Location: Poster Hall 2

• - Enhancing AAV Production Efficiency through Plasmid Modification and Dual-Plasmid Systems (AMA1043)

- Date: May 13th, 6 PM - 7:30 PM
- Location: Poster Hall 2

• - Rationally Designed Chimeric AAV Capsids Demonstrate Reduced Liver Tropism and Enhanced Muscle Transduction (AMA1049)

- Date: May 14th, 5 PM - 7:30 PM
- Location: Poster Hall 2

• - Rapid AAV Capsid Quantification Using Multi-Angle Dynamic Light Scattering for In-Process Manufacturing (AMA1050)

- Date: May 14th, 5 PM - 7:30 PM
- Location: Poster Hall 2

• - Evaluating Neutralizing Antibodies Against AAVs Using a High-Sensitivity LacZ Reporter Assay (AMA1053)

- Date: May 15th, 5 PM - 7:30 PM
- Location: Poster Hall 2

The abstracts of these presentations can be accessed publicly through the ASGCT website. Moreover, PackGene will have a representation at booth 1821, inviting attendees to engage more personally about their pioneering technologies and data-driven insights.

About PackGene Biotech, Inc.

PackGene is recognized globally as a leading Adeno-Associated Virus (AAV) vector provider specializing in the development of cost-effective and scalable AAV production. Utilizing its proprietary π-Alpha 293 AAV High-Yield Platform, the company significantly increases AAV production efficiency, enabling substantial advancements in gene therapy and related clinical applications. By integrating upstream and downstream quality by design (QbD) optimizations, PackGene ensures that the total AAV yield can increase significantly, contributing to the efficacy of gene therapy treatments.

For further details, interested parties can visit PackGene's official site at PackGene.com, where extensive resources and contact avenues are available for engagement.

With a strong vision for the future of gene therapy, PackGene is dedicated to facilitating advancements that not only support technological evolution but also ensure that such treatments become widely accessible for those in need.